Categories
Non classé

Complete Health Check-Up: What Is Worth

A modern preventive health check-up can range from a few hundred euros for a focused cardiovascular and metabolic assessment to more than €15,000 for whole-body MRI, genomics, liquid biopsy, brain imaging and biological-age measurements. The difficult question is not how much can be measured. It is which measurements are likely to change a useful decision.

For a generally healthy adult, the best check-up is therefore not necessarily the one with the longest laboratory list or the most impressive scanner. A high-value programme should first identify the major modifiable risks that medicine already knows how to treat, make sure established screening and vaccination are up to date, establish a small number of useful baselines, and create a mechanism for following abnormal results. Advanced imaging and molecular diagnostics can then be added selectively.

This distinction matters because preventive medicine is undergoing an unusual transition. Conventional European healthcare systems are very good at treating recognised disease and increasingly good at organised screening for specific conditions, yet they remain fragmented when a healthy person wants one coherent assessment spanning cardiovascular risk, metabolism, cancer prevention, physical capacity, sleep, cognition and long-term follow-up.

Private preventive-health companies are trying to fill that gap. Some genuinely reduce friction. Others also sell tests for which the clinical evidence is substantially less mature than the technology.

Contents

1. Why consider a comprehensive health check-up?

The useful purpose of a comprehensive check-up is to assemble components intelligently, rather than assuming that a large bundle of unrelated tests automatically improves outcomes.

A well-designed check-up can offer four practical benefits:

  • Compression: several weeks of appointments can be consolidated into one or two coordinated days.
  • Integration: laboratory results, imaging, family history, lifestyle and physical performance can be interpreted together rather than in specialist silos.
  • Baseline creation: measurements such as blood pressure, ApoB, HbA1c, aerobic fitness or selected cognitive measures become more useful when followed longitudinally.
  • Follow-through: a good programme converts abnormalities into decisions, referrals and repeat measurements rather than simply issuing a 70-page report.

This last point may be the most valuable. Information without a pathway to action is an expensive form of curiosity.

2. What European healthcare systems often do less well

European healthcare differ substantially in financing, access, waiting times and preventive programmes. There are nevertheless recurring structural limitations.

Prevention is often disease-specific rather than integrated

Public systems generally prioritise interventions with demonstrated population benefit. This is rational. It means, however, that cardiovascular assessment may sit with a GP, colon screening with another programme, dermatology elsewhere, exercise testing in sports medicine, and cognitive assessment largely outside routine preventive care.

A consumer wanting one longitudinal picture can end up assembling it manually.

The system is designed primarily around clinical need

Public medicine must allocate finite resources. This creates a market for private programmes that offer convenience and broader measurement to people willing to pay.

Waiting times and fragmentation remain real

Eurostat reported that 3.6% of people aged 16 and above in the EU who needed a medical examination or treatment in 2024 said they could not obtain it because of cost, waiting lists or distance. The variation between countries was enormous.

At the same time, hundreds of thousands of deaths in the EU are classified as preventable through effective public-health measures. The lesson is not that Europe needs an MRI scanner for every healthy person. It is that prevention, access and implementation remain unfinished work.

3. What should actually be included in a comprehensive check-up?

We would divide a preventive assessment into three layers: Core, Targeted Add-ons, and Exploratory/Premium.

Layer 1: Core — the highest-value foundation

Component What it contributes Guidefinances value view
Medical and family history Identifies inherited risk, previous disease, medication exposure and symptoms that change screening priorities Essential
Blood pressure and cardiovascular risk One of the most actionable predictors of long-term cardiovascular disease Essential
Lipid profile LDL-C, HDL-C, triglycerides; ApoB can improve assessment of atherogenic particle burden Essential; ApoB is a useful enhancement
Lipoprotein(a) Largely genetically determined cardiovascular risk marker High-value once-in-adulthood measurement for many people
Glucose metabolism Fasting glucose and/or HbA1c; further testing when indicated Essential
Kidney and liver function Creatinine/eGFR, liver enzymes and relevant additional chemistry Core laboratory medicine
Blood count Anaemia and selected haematological abnormalities Core
Weight, waist and body composition Metabolic risk, muscle and fat distribution Useful; trends matter more than a single number
Exercise and physical capacity Strength, aerobic capacity and functional baseline Underused and highly actionable
Smoking, alcohol, nutrition and sleep review Identifies major modifiable exposures Essential
Mental health Depression, anxiety, stress and functional wellbeing where appropriate Should not be omitted
Vaccination review Checks nationally recommended immunisation status High value, low glamour
Evidence-based cancer screening Screening selected by age, sex, family history and jurisdictional guidance Essential where indicated
Dental, eye, hearing and skin review Risk-based preventive assessment Often worth integrating

This is the unglamorous part of longevity medicine. It is also where much of the real value sits.

Layer 2: Targeted add-ons

The second layer should be selected according to history and baseline risk rather than purchased automatically.

  • DEXA: useful for bone density when clinically appropriate and increasingly useful for quantitative body-composition tracking.
  • ECG: inexpensive, but its screening value depends on context.
  • Echocardiography: valuable when there is a relevant clinical indication; considerably less compelling as universal annual screening.
  • Coronary artery calcium CT: can meaningfully refine cardiovascular risk in selected people, but uses ionising radiation and should answer a defined treatment question.
  • Carotid ultrasound: potentially helpful in selected vascular assessments, but not a universal screening requirement.
  • Exercise ECG or cardiopulmonary exercise testing / VO2 max: especially useful where fitness, symptoms or cardiovascular performance are relevant.
  • Targeted ultrasound: thyroid, abdominal or vascular imaging when history or examination justifies it.
  • Colonoscopy: an established diagnostic and screening tool in appropriate populations, not something whole-body MRI replaces.
  • Dermatological imaging: potentially valuable for people with multiple naevi, significant sun exposure or elevated melanoma risk.
  • Sleep testing: high value where sleep apnoea or another sleep disorder is suspected.
  • Formal neuropsychological testing: appropriate when symptoms, family history or another neurological concern makes the result actionable.

Layer 3: Exploratory and premium diagnostics

Test Potential attraction Main limitation Guidefinances tier
Whole-body MRI Large amount of anatomical information without ionising radiation No established mortality benefit for routine asymptomatic population screening; incidental findings Advanced / exploratory
Multi-cancer early detection blood tests Potential detection of cancers for which no conventional screening programme exists Outcome evidence and optimal downstream pathways remain under development Exploratory
Whole-genome sequencing Can identify selected actionable inherited variants; data can be reinterpreted Many findings are uncertain or do not change management Targeted to exploratory
Polygenic risk scores Potential refinement of lifetime disease risk Clinical utility varies by disease and population Exploratory
Epigenetic/biological-age clocks Interesting longitudinal research signal Changing the number has not been shown to extend an individual’s lifespan Exploratory
Microbiome testing Rich biological data Consumer results often lack a validated treatment decision Usually low priority
Continuous glucose monitor without diabetes Can provide behavioural feedback on food and exercise May generate noise and unnecessary food anxiety; clinical outcome advantage is uncertain in healthy users Optional behavioural tool
Wearables and recovery scores Cheap longitudinal measurement of activity, sleep and heart-rate patterns Proprietary scores should not be confused with clinical diagnosis Useful widget when it changes behaviour
PET-CT screening Very broad functional/anatomical imaging Radiation exposure, incidental findings and weak case for routine healthy-population screening Not a routine longevity purchase

4. Brain and cognitive health: the neglected component

Brain health is an interesting weakness of many traditional executive check-ups. Programmes frequently measure dozens of cardiovascular biomarkers while devoting little attention to cognition, sleep, mood, hearing and neurological function—even though these domains have enormous implications for quality of life.

That does not mean every healthy adult needs a dementia work-up.

Even in asymptomatic adults aged 65 and over, the US Preventive Services Task Force has concluded that evidence remains insufficient to determine whether universal cognitive screening produces more benefit than harm. In a younger general population the case for disease-oriented routine screening is weaker still.

A more rational brain-health layer has several steps.

Level 1 — protect the brain by measuring what we already know matters

Blood pressure, lipids, glucose metabolism, smoking, exercise, sleep, hearing, mood and alcohol exposure belong in a brain-health strategy because vascular and general health strongly influence later neurological risk.

Level 2 — optional cognitive baseline

A short validated or well-standardised digital battery measuring domains such as processing speed, attention, executive function and memory can create a baseline. The value comes mainly from reproducible longitudinal comparison, not from interpreting tiny differences as disease.

Singapore’s IHH Healthspan Pioneer programme, for example, explicitly includes a digital brain-function screen. Fountain Life advertises neurocognitive screening, and Human Longevity combines brain MRI with NeuroQuant volumetry.

Level 3 — formal assessment when there is a question to answer

Subjective cognitive change, unusual neurological symptoms, a strong family history or an abnormal baseline may justify formal neuropsychological testing and neurological assessment.

Level 4 — brain MRI and volumetry

A structural brain MRI can detect clinically important abnormalities, but using MRI or AI-derived brain volume as a routine annual wellness score is much less established.

Volumetry may be scientifically interesting. A small difference from a normative database is not automatically a disease and does not automatically create a useful intervention.

Level 5 — Alzheimer’s biomarkers

Blood biomarkers including phosphorylated tau are advancing rapidly and are increasingly useful in the diagnostic evaluation of people with suspected Alzheimer’s disease. That is different from population screening of asymptomatic people.

For preventive-health consumers, this remains a field where the technology is progressing faster than consensus about whom to test.

5. Whole-body MRI: useful technology, uncertain screening outcome

Whole-body MRI is arguably the flagship technology of the new private longevity clinics.

Its strengths are genuine. MRI provides extensive soft-tissue imaging without ionising radiation and may identify renal masses, liver lesions, aneurysms, structural abnormalities and other previously unknown findings.

The difficulty is the screening problem.

The American College of Radiology states that there is insufficient evidence to recommend total-body MRI for asymptomatic people without relevant symptoms, risk factors or family history. It also notes the absence of documented evidence that population total-body screening prolongs life or is cost-effective.

The concern is not primarily the MRI itself. It is what happens afterwards.

A sufficiently detailed scan of an apparently healthy person is likely eventually to find something: a cyst, nodule, anatomical variant, borderline enlargement or indeterminate lesion. Some findings are important. Others initiate repeat MRI, CT, ultrasound, biopsy, specialist appointments and months of uncertainty without improving health.

This is the central economics of advanced screening:

The €2,000 scan is not necessarily the relevant cost. The diagnostic cascade is.

Whole-body MRI also does not eliminate the need for established cancer screening. It is not a superior universal replacement for colonoscopy or stool-based colorectal screening, cervical screening, mammography where indicated, low-dose lung CT in selected high-risk populations, or organ-specific investigation.

Our classification is therefore:

Whole-body MRI is a rational premium option for a well-informed consumer who values additional anatomical information and accepts the possibility of incidental findings. It is not currently a foundational requirement for preventive medicine.

6. What adds health value—and what mostly adds data?

Measure Actionability Evidence maturity Typical cost impact Value assessment
Blood pressure, lipids, metabolic risk Very high High Low Excellent
Guideline-based cancer prevention High High for established programmes Low–medium Excellent
Exercise capacity / fitness High High as risk/health marker Low–medium Excellent
ApoB / Lp(a) High where they refine cardiovascular management High/moderate Low Very good
DEXA Moderate–high when indicated High for bone density Low–medium Good
Cognitive baseline Moderate Moderate depending on test and purpose Low Interesting add-on
Coronary calcium CT High in appropriately selected risk groups Substantial Medium Targeted high value
Whole-body MRI Variable Insufficient for routine population outcome benefit High Premium option
Whole-genome sequencing High for a small subset of findings; low for many others Mixed Medium Potentially worthwhile once
Multi-cancer liquid biopsy Potentially high Still developing High Exploratory
Epigenetic age Low today Research-stage as a consumer treatment target Medium Mostly information
Consumer microbiome profiling Usually low Immature for broad clinical use Medium Low priority

7. The most interesting European jurisdictions

European consumers have an advantage over Americans interested in preventive diagnostics: it is often possible to assemble much of the clinically useful package for substantially less money, although integration and concierge follow-up can be weaker.

Germany — probably the strongest all-round European choice

Germany combines large academic medical centres, advanced imaging, private preventive medicine and relatively transparent pricing.

Charité Berlin represents the medically conservative end of the spectrum. Its private check-up is approximately €1,200–€1,620 depending on investigations, with MRI, CT, gastroscopy and colonoscopy used according to medical indication.

YEARS Berlin represents the new longevity model:

  • Core: €1,900
  • Evolve: €7,600, including whole-body MRI and multi-cancer detection
  • Ultimate: €16,900, adding genomics, epigenomics, microbiome and experimental longevity markers

The Core programme is arguably more interesting from a value perspective than Ultimate. It includes extensive laboratory testing, cardiovascular assessment, VO2 max / cardiopulmonary exercise testing, lung testing, ultrasound and physician integration without automatically charging for every emerging technology.

Guidefinances view: Germany is our preferred European jurisdiction for the reader who wants strong conventional medicine with the option of adding sophisticated private diagnostics.

Switzerland — high medical quality, high price, good imaging access

Switzerland naturally appeals to residents who value local follow-up and want imaging interpreted within the Swiss medical system.

360Prevent lists whole-body MRI including a physician review from CHF 1,980, with laboratory testing available for an additional CHF 250.

Ahead Health lists:

  • Core whole-body MRI: CHF 1,990
  • Advanced: CHF 2,490
  • Pro: CHF 3,549, adding AI brain volumetry, additional musculoskeletal MRI and expanded laboratory testing

Compared with premium US longevity clinics, these prices are not unreasonable. The principal limitation is that an MRI package is not automatically a complete preventive-health programme. Cardiovascular risk, cancer screening, fitness, vaccination, cognitive assessment and ongoing primary care still need integration.

Guidefinances view: excellent for sophisticated imaging and convenient follow-up, but a modular Swiss strategy can offer better value than buying the broadest possible package.

United Kingdom — unusually good budget innovation

The most interesting UK option is not necessarily an MRI clinic.

Neko Health currently charges £299 for its approximately one-hour health scan. Its system combines sensor-based measurements, skin assessment, cardiovascular/metabolic evaluation and blood analysis rather than whole-body MRI.

This makes Neko conceptually interesting: instead of making prevention more expensive by adding a scanner, it attempts to industrialise relatively low-cost measurement and physician review.

Prenuvo has also opened a London whole-body MRI centre, giving the UK a premium imaging route, while established groups such as Bupa provide more conventional physician-led health assessments.

Guidefinances view: perhaps the most interesting European jurisdiction for a lower-cost technology-enabled baseline, with advanced imaging available separately if justified.

Sweden — integrated premium diagnostics

Stockholm-based Executive Health currently advertises its Executive Premium programme at SEK 62,500, approximately €5,500. It combines physician consultation, cardiovascular diagnostics, laboratory and functional testing with full-body MRI and follow-up.

This sits between German conventional executive medicine and the much more expensive US longevity model.

Guidefinances view: attractive for buyers who want MRI genuinely integrated into a physician-led one-day evaluation.

Spain — attractive modular economics

Executive Health Spain has publicly advertised comprehensive preventive examinations around €1,700 and whole-body MRI around €800. These prices should be reconfirmed before booking because the public pricing information is less recently documented than several other providers in this comparison.

The broader advantage of Spain is access to high-quality private medicine at a lower cost base than Switzerland or northern Europe.

Guidefinances view: potentially excellent value, particularly for readers willing to construct a modular programme rather than buy a branded longevity membership.

Türkiye — strongest budget proposition

Türkiye has developed a substantial international medical market, and comprehensive check-ups can be strikingly inexpensive.

Anadolu Medical Center currently lists:

  • Essential: $449
  • Comprehensive: $896
  • Premium: $1,651

It allows modules including advanced cardiology, memory/cognitive assessment, gastrointestinal screening, metabolic evaluation and full-body MRI to be added.

This is close to the ideal modular structure: buy a strong core, then add tests because they answer a question rather than because they are included in a marketing bundle.

The disadvantage is longitudinal care. A €1,500 trip abroad looks less cheap if an uncertain finding requires repeated specialist follow-up back home.

Guidefinances view: probably the best pure diagnostic value in this European selection, especially when the programme is carefully specified in advance.

8. Europe: summary table

Jurisdiction Example providers Indicative budget Advanced imaging Brain/cognition Guidefinances view
Germany Charité, YEARS, Medinstitut Berlin €1,200–€1,900 core; €4,000–€7,600 advanced; €16,900 experimental premium Excellent Available in premium programmes Best European all-rounder
Switzerland 360Prevent, Ahead Health Approx. CHF 1,980–3,549 for MRI-led programmes Excellent Brain MRI / volumetry available Best for Swiss-based follow-up
United Kingdom Neko Health, Bupa, Prenuvo From £299 core tech-enabled assessment; MRI premium separate Available Variable Most interesting budget innovation
Sweden Executive Health Stockholm SEK 62,500 / about €5,500 premium programme Whole-body MRI included Programme-dependent Strong integrated premium option
Spain Executive Health Spain and private hospital networks Historically around €1,700 + €800 MRI; verify current quote Good Available through specialists Potential modular value
Türkiye Anadolu Medical Center $449–$1,651 base plus modules Optional full-body MRI Dedicated memory/cognitive module Best budget proposition

9. Worldwide options

United States — maximum integration, maximum price

The US leads the premium longevity-clinic market.

Human Longevity currently lists its Executive Health programme at $8,000 annually. It includes whole-genome sequencing, whole-body MRI, a dedicated brain MRI with NeuroQuant, extensive blood biomarkers, echocardiography, ECG, DEXA and coronary calcium CT.

That is a genuinely broad diagnostic bundle and notably cheaper than some concierge competitors.

Fountain Life sits further towards premium longitudinal longevity care. Its APEX membership is currently publicly offered at $21,500 and integrates whole-body/brain MRI, biomarker testing, physician oversight and additional optimisation services.

Here the premium is not simply paying for tests. It is paying for integration, repeat testing, infrastructure, service and a continuing relationship.

Whether that is worth more than $20,000 every year is a different question.

Singapore — premium Asian prevention with a strong brain-health component

IHH Healthcare Singapore launched a particularly interesting Healthspan model in 2026.

Its Pioneer programme costs S$19,620 and incorporates advanced imaging, genomic testing, a digital brain-function screen, MRI stroke screening, epigenetic-age testing and a substantial coaching programme.

Singapore’s advantage is not low price. It is medical infrastructure, English-language care and the ability to combine hospital-grade diagnostics with preventive-health services.

Guidefinances view: one of the strongest Asian premium competitors to the US longevity-clinic model.

South Korea — perhaps the strongest advanced-imaging value

South Korea has a mature culture of hospital-based comprehensive health screening.

Samsung Medical Center currently lists approximately:

  • KRW 1.874 million for its Primary Basic programme;
  • KRW 2.838–2.990 million for executive programmes;
  • KRW 7.857 million for its Premium programme with extensive MRI and PET-CT imaging.

Korean programmes can be exceptionally comprehensive, but more scanning is not automatically better screening. In particular, a package containing PET-CT or multiple CT examinations should be evaluated partly on radiation burden and clinical purpose, not simply on the quantity of technology included.

Guidefinances view: outstanding diagnostic infrastructure and excellent value for consumers deliberately seeking sophisticated imaging.

Thailand — inexpensive conventional executive medicine

Bangkok Hospital currently advertises its CEO programmes at THB 129,000 for men and THB 135,000 for women, incorporating broad organ-system and cardiovascular assessment.

Lower-priced executive programmes are available across the Thai hospital market.

Thailand therefore remains attractive for a conventional hospital-based executive examination, although international patients should ensure that records are supplied in a format their home physician can use.

Guidefinances view: strong conventional value; less compelling if the objective is the newest genomic or brain-imaging technology.

10. Worldwide summary table

Jurisdiction Example Indicative budget Distinctive feature Main caveat Guidefinances view
United States Human Longevity $8,000/year Genome + whole-body MRI + NeuroQuant brain MRI + cardiac imaging Considerable testing; annual cost Strong premium value by US standards
United States Fountain Life APEX $21,500 Integrated longitudinal longevity model Very high recurring cost; some optimisation components have weaker outcome evidence Premium convenience rather than necessity
Singapore IHH Healthspan Pioneer S$19,620 Genomics, imaging, digital brain assessment and coaching Premium pricing Best integrated Asian premium model
South Korea Samsung Medical Center KRW 1.874m basic to ~7.857m premium Hospital-grade MRI/PET-CT and extensive diagnostics Potential over-screening/radiation in top packages Excellent advanced-diagnostics value
Thailand Bangkok Hospital Approx. THB 129k–135k for CEO programme Comprehensive hospital-based executive screening Follow-up abroad can complicate economics Strong conventional value
Türkiye Anadolu Medical Center $449–$1,651 + options Very inexpensive modular medical screening Travel and downstream care Global budget winner

 

11. How Guidefinances would build a comprehensive check-up

Budget 1: the rational core

Indicative target: roughly €500–€1,500 depending on country and what is already covered by insurance.

Priorities:

  • long physician consultation and family-history review;
  • blood pressure and cardiovascular risk;
  • CBC, kidney/liver function and appropriate metabolic laboratory testing;
  • lipid profile, preferably including ApoB where useful;
  • Lp(a) at least once unless previously established;
  • HbA1c/glucose;
  • appropriate evidence-based cancer screening;
  • vaccination review;
  • weight, waist and body-composition assessment;
  • physical performance or aerobic fitness;
  • sleep, mental health, smoking and alcohol;
  • follow-up consultation with a written action plan.

This is where we would spend first.

Budget 2: advanced but disciplined

Indicative target: approximately €1,500–€4,000.

Add selectively:

  • DEXA;
  • VO2 max / cardiopulmonary exercise testing;
  • targeted cardiac imaging or coronary calcium when it changes cardiovascular management;
  • dermatology / total-body skin imaging where relevant;
  • formal sleep testing where suspected;
  • a reproducible digital cognitive baseline;
  • targeted ultrasound or specialist assessment.

This range probably offers the best balance between conventional preventive medicine and genuinely useful deeper measurement.

Budget 3: premium imaging

Indicative target: approximately €3,000–€7,500.

Add whole-body MRI if the buyer understands:

  • mortality benefit has not been demonstrated for routine screening;
  • incidental findings are expected;
  • the provider must have a clear pathway for follow-up;
  • the scan does not replace conventional cancer screening.

A high-quality cognitive baseline and brain MRI can also be considered when there is a genuine neurological or longitudinal reason.

Budget 4: exploratory longevity

€7,500 to €20,000+.

This is where programmes begin adding combinations of:

  • whole-genome sequencing;
  • multi-cancer liquid biopsy;
  • epigenetic age;
  • microbiome analysis;
  • AI brain volumetry;
  • large biomarker panels;
  • continuous monitoring;
  • concierge medicine;
  • coaching and “optimisation” services.

Some of these technologies may become important parts of mainstream prevention. Some may not.

The purchaser should therefore ask a simple question for every item:

If this result is abnormal tomorrow morning, what exactly will I do differently?

If neither the patient nor the physician can answer that question, the test is probably information rather than medicine.

13. Guidefinances conclusion

A comprehensive health assessment can be a rational use of money, particularly for a person whose ordinary healthcare is fragmented, who has not systematically reviewed cardiovascular and cancer risk, or who values the convenience of consolidating many assessments into one carefully managed programme.

But the economics become less attractive as the programme moves from established prevention toward indiscriminate detection.

Our hierarchy is straightforward:

Foundation: cardiovascular and metabolic risk, appropriate cancer screening, vaccination, exercise and strength, sleep, mental health, smoking/alcohol, family history and a physician who follows the results.

Targeted: ApoB/Lp(a), DEXA, advanced cardiovascular assessment, formal sleep evaluation, specialist imaging and cognitive assessment when individual risk makes them useful.

Premium: whole-body MRI for an informed buyer willing to accept uncertain outcome benefit and incidental findings.

Exploratory: multi-cancer liquid biopsy in broad asymptomatic populations, biological-age testing, extensive consumer microbiome analysis and many “longevity biomarker” panels.

For Europe, Germany currently looks like the strongest overall jurisdiction because it combines rigorous conventional medicine with sophisticated private diagnostics. Türkiye offers the strongest headline value, provided downstream follow-up is planned. Switzerland makes sense for residents who value continuity and local imaging. The UK deserves attention because Neko demonstrates that technology-enabled prevention does not necessarily have to become more expensive.

Globally, the United States offers the deepest vertically integrated programmes but at a considerable recurring premium. Singapore provides perhaps the strongest Asian equivalent. South Korea delivers exceptional hospital-based diagnostic depth for the money.

The larger lesson is that the €20,000 longevity clinic is not the only route to serious preventive medicine.

The expensive part is increasingly easy to buy. The difficult part is deciding what is worth knowing.

14. Selected sources

Editorial note: Provider prices, availability and programme descriptions were reviewed on 14 August 2026. Private preventive-health packages change frequently, and current inclusions and prices should be confirmed directly before booking. This article discusses preventive-health purchasing and is not a personalised medical recommendation. Screening should be adjusted for symptoms, family history, prior findings, medications and individual risk.

“`